沃森生物(300142.SZ)：签署微生态健康靶向技术独家再许可协议之修正案

Core Viewpoint - Watson Bio (300142.SZ) has signed an amendment to its exclusive sublicense agreement with Notitia Biotechnologies Company to enhance its market competitiveness and expand its core microbiome therapy in the field of precise micro-ecological health and functional nutrition intervention [1] Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1] - This agreement is based on the upstream licensing agreement that Notitia has with Rutgers University in New Jersey, USA [1] Group 2: Strategic Implications - The signing of this amendment signifies a dual-track layout for the company, combining "disease treatment intervention" with "chronic disease prevention and health nutrition" [1] - The initiative aligns with national policies on non-drug interventions and emphasizes the importance of chronic disease nutrition and prevention strategies [1] Group 3: Market Positioning - The company aims to provide a comprehensive health solution that covers in-hospital treatment, out-of-hospital management, and multi-scenario interventions [1] - This move is expected to integrate existing clinical pathways and underlying technology platform construction, offering diverse product forms to address sub-health and high-risk chronic disease populations [1]